United Therapeutics Corporation
UTHRNASDAQHealthcare● Active
$549.87
+$2.18(+0.40%)
Market Cap$23.3B
P/E Ratio—
52W High$609.35
52W Low$272.12
United Therapeutics Corporation (UTHR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · UTHR · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $1.33B | $1.20B | $0.98B | $0.73B | $0.48B |
| Depreciation & Amort. | $0.09B | $0.07B | $0.05B | $0.05B | $0.05B |
| Stock-Based Comp. | $0.15B | $0.14B | $0.04B | $0.11B | $0.14B |
| Change in Working Capital | ($0.11B) | ($0.06B) | ($0.10B) | ($0.14B) | ($0.17B) |
| Net Cash from Operations | $1.56B | $1.33B | $0.98B | $0.80B | $0.60B |
| Investing Activities | |||||
| Capital Expenditure | ($0.52B) | ($0.25B) | ($0.23B) | ($0.14B) | ($0.12B) |
| Purchases of Investments | ($3.46B) | ($1.65B) | ($2.51B) | ($1.71B) | ($1.90B) |
| Sales of Investments | $1.58B | $2.37B | $2.14B | $1.03B | $1.53B |
| Net Cash from Investing | ($0.55B) | $0.42B | ($0.72B) | ($0.81B) | ($0.49B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($1.00B) | ($1.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.30B) | ($0.40B) | ($0.10B) | $0.00B | $0.00B |
| Net Cash from Financing | ($1.15B) | ($1.25B) | ($0.01B) | $0.08B | $0.04B |
| Free Cash Flow | |||||
| Free Cash Flow | $1.04B | $1.08B | $0.75B | $0.66B | $0.48B |
| FCF Margin %(computed) | 32.70% | 37.55% | 32.12% | 34.28% | 28.32% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more United Therapeutics Corporation data
About United Therapeutics Corporation (UTHR) Cash Flow Statement
United Therapeutics Corporation generated operating cash flow of $1.56B and free cash flow of $1.04B for 2025 — a FCF margin of 32.70%. Capital expenditure was ($0.52B).
Frequently asked questions
UTHR · 4 questionsUnited Therapeutics Corporation generated free cash flow of $1.04B for 2025, down 3.7% year-over-year.
UTHR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08